Sheller 11th Street Family Health Supports Alumni Turkey Drive

The Stephen and Sandra Sheller 11th Street Family Health Services of Drexel University is one of the many ways that the Sheller family gives back to the community. Since the health center’s inception in 1996, it has been a community partner helping Drexel Alumni distribute holiday meals to those in need. Drexel’s Annual Holiday Charity […]

Superior Court Upholds $70M Risperdal Verdict

risperdal, boy,sad,breasts,sheller,lawsuit,lawyer,verdict

A Pennsylvania Superior Court has rejected Johnson & Johnson’s appeal of a 2016 $70 million verdict awarded to a 20 year-old Tennessee man, Andrew Yount (A.Y.) who developed gynecomastia after taking the antipsychotic drug Risperdal since he was 4-1/2 years old. Gynecomastia is an irreversible condition caused by an increase in the hormone prolactin and […]

Sheller Gives Presentations on Risperdal and Opioid Litigation

Stephen A. Sheller, founder of Sheller PC, is often sought for his expertise in litigation against pharmaceutical manufacturers whose products cause harm to consumers. He recently has one of few private law firms chosen to work with the City of Philadelphia in opioid litigation. In October 2019 Sheller was an invited speaker at two conferences. October 12, 2019 “Big […]

Positive Developments in Risperdal Litigation in August

scales,of,justice,law,firm,lawyer,lawsuit,sheller,attorney,national,case,class,action,mass,tort

Several positive developments this month for young men injured from taking the Risperdal. Risperdal is an anti-psychotic drug manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals. The drug’s side effects included gynecomastia, the growth of female-like breast in young boys. $2.5M Jury Verdict Stands The Supreme Court of Pennsylvania has declined to hear an appeal of […]

Sheller on Thom Hartman Radio Show

From The Ring of Fire: Why Is Big Pharma Increasing Your Medicine Prices? By Thom Hartmann – July 17, 2019 The US pays more for medical drugs that in any country in the world. Health in the US is all about making a profit and drug prices have increased dramatically since Trump become president. Drug […]

New Trial for Risperdal Injury Previously Tossed

Risperdal,FDA,petition,sheller,approval,appeal,woodcock,janet

In another win for plaintiffs injured by Risperdal, a Pennsylvania appellate court reversed a trial courts decision to grant the defendants motion for nonsuit, mid-trial. This decision will send the case back to the Pennsylvania Courts of Common Pleas for retrial. In the 2016 case of T.M. vs Janssen Pharmaceuticals, the trial judge decided mid-trial […]

April 23rd, Book Signing: Big Pharma Big Greed

  When: Tuesday, April 23, 2019 Time: 5:30 PM Location: Shakespeare & Co., 1632 Walnut Street, Philadelphia, PA 19103 Description: Big Pharma, Big Greed: The Inside Story of One Lawyer’s Battle to Stem the Flood of Dangerous Medicines and Protect Public Health An update and expansion of Sheller’s previous book with Sidney Kirkpatrick “Pharmageddon: A […]

Family Stranded in Cold Under ‘Live Stop’ Policy

The controversial Philadelphia Police Department ‘Live Stop’ policy makes headlines again as local resident and criminal justice activist, Reuben Jones, was left on the side of the road in the extreme cold with his two children after police impounded his car for an expired registration. It is against PPD policy to leave drivers and their passengers […]

Conflicts of Interest in Medical Research

In Stephen Sheller’s book Lawyering In Times of Saints and Evil Doers (2015), Sheller tells the story of science for sale, the widespread conflict of interest created when doctors and researchers are influenced by payments they receive from pharmaceutical companies. In 2008, a Congressional inquiry led by Senator Charles E. Grassley (R-IA) exposed the extensive conflict of interest […]

$2.5 M Risperdal Verdict Upheld in Superior Court

The Pennsylvania Superior Court has upheld the 2015 $2.5 million Risperdal verdict for plaintiff Austin Pledger. Pledger’s case was the first Risperdal case to go to trial. Viewed as a huge win for plaintiffs, the decision bodes well for the future litigation of 6,500 plaintiffs whose suits against Janssen Pharmaceutical, a subsidiary of Johnson & […]